Jiangsu Hengrui Medicine
600276.SS
#484
Rank
NZ$72.80 B
Marketcap
$11.41
Share price
-3.83%
Change (1 day)
3.35%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Operating Margin for Jiangsu Hengrui Medicine (600276.SS)

Operating Margin as of November 2024 (TTM): 22.87%

According to Jiangsu Hengrui Medicine 's latest financial reports and stock price the company's current Operating Margin is 22.87%. At the end of 2022 the company had an Operating Margin of 18.65%.

Operating Margin history for Jiangsu Hengrui Medicine from 2002 to 2024

Operating Margin at the end of each year

Year Operating Margin Change
202218.65%8.19%
202117.24%-30.66%
202024.86%-4.39%
201926.00%0.67%
201825.83%-4.93%
201727.17%0.03%
201627.16%-1.24%
201527.50%13.88%
201424.15%1.32%
201323.84%-3.79%
201224.77%5.85%
201123.41%1.87%
201022.97%-10.86%
200925.77%31.2%
200819.65%-23.22%
200725.58%27.05%
200620.14%7.6%
200518.72%24.13%
200415.08%5.09%
200314.35%-1.85%
200214.62%-5.07%
200115.40%

What is a company's Operating Margin?

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.